{"nctId":"NCT03002038","briefTitle":"Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients","startDateStruct":{"date":"2015-09"},"conditions":["Neuromyelitis Optica Spectrum Disorder"],"count":86,"armGroups":[{"label":"Azathioprine","type":"EXPERIMENTAL","interventionNames":["Drug: Azathioprine"]},{"label":"Rituximab","type":"EXPERIMENTAL","interventionNames":["Drug: Rituximab"]}],"interventions":[{"name":"Azathioprine","otherNames":["Azathioprine Mehrdaru®"]},{"name":"Rituximab","otherNames":["RediTux®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of neuromyelitis optica spectrum disorder based on the recent guidelines in 2015\n* Expanded disability status scale between 0 and 7\n* Age between 18 and 50 years old\n\nExclusion Criteria:\n\n* Pregnancy or lactation during the study\n* Deciding to leave the study by patient\n* Lack of consent to enter the study\n* Lack of cooperation for follow up\n* Severe side effect of the medication\n* Treatment with other immunosuppressant medications (including but not limited to cyclophosphamide, mycophenolate mofetil, methotrexate, others) within two months before intervention\n* Taking any other immunosuppressant or other type of medication (including herbal drugs) without permission of the physician during the study.\n* Presence of other autoimmune disease (including but not limited to Behcet disease, systemic lupus erythematosus, rheumatoid arthritis, and others)\n* Presence of liver disorders\n* Presence of hematologic disorders\n* Presence of heart failure\n* Receipt of a live vaccine within 4 weeks prior to intervention\n* Previous treatment with Azathioporine or Rituximab\n* History of HIV, hepatitis B, or hepatitis C\n* Ongoing daily steroid use\n* History of severe allergic or anaphylactic reaction to monoclonal antibodies","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"50 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Annual Relapse Rate","description":"annual relapse rate will be measured in the baseline (according to patients' history in the last year) and after 12 months of intervention.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":"0.38"},{"groupId":"OG001","value":"1.30","spread":"0.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.51","spread":"0.55"},{"groupId":"OG001","value":"0.21","spread":"0.42"}]}]}]},{"type":"SECONDARY","title":"Expanded Disability Status Scale","description":"expanded disability status scale will be measured in the baseline and after 12 months of intervention.\n\nExpanded disability status scale (EDSS) is a measure of disability for patients. The score ranges from 0-10, with 0 showing normal neurological exam and 10 showing death due to the disabling disease. Thus, higher scores represent more profound levels of disability.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.40","spread":"1.24"},{"groupId":"OG001","value":"3.55","spread":"1.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.95","spread":"1.13"},{"groupId":"OG001","value":"2.56","spread":"1.99"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Adverse Drug Reactions","description":"adverse drug reactions will be observed closely and reported during the intervention. We will compare the number of adverse drug reactions in two groups. Also, adverse drug reactions will be described by details in each group.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":46},"commonTop":["Mild/moderate allergic reactions","Gastrointestinal intolerance"]}}}